文献速递流行病学与生物统计临床试验与 GCP

生物类似药III期试验的贝叶斯分析方法

Bayesian methods for analysis of biosimilar phase III trials.
PubMed 文献 · Stat Med · 2018-05-23

生物类似药开发需遵循逐步证据链,III期试验旨在确认其与参照生物药在有效性、安全性和免疫原性上的相似性。本文提出为III期试验构建合理的先验信息:参照药基于已发表结果的荟萃分析设定疗效概率先验,生物类似药则依据早期步骤证据强度设定先验。模拟研究显示,贝叶斯相对风险分析在多数情形下功效更高、90%可信区间更短且频率学覆盖超过90%,均方根误差更优。

要点

  • 生物类似药III期试验可采用贝叶斯方法,通过合理先验信息降低所需样本量。
  • 参照药疗效先验可基于已发表结果的荟萃分析设定。
  • 生物类似药先验可依据早期分析及药代/药效相似性证据强度设定。

核心结论

  • 贝叶斯相对风险分析在生物类似药III期试验中,多数情形下较传统方法功效更高、90%可信区间更短且频率学覆盖超过90%,均方根误差更优。

研究设计与样本

  • 方法学研究,提出为生物类似药III期试验构建先验信息的贝叶斯分析框架,并通过模拟研究评估性能。

主要发现

  • 模拟研究显示,贝叶斯相对风险分析除少数例外,提供更高功效、更短的90%可信区间(频率学覆盖超过90%)和更好的均方根误差。

关键数值与推荐

  • 参照药疗效概率的先验通过已发表结果的荟萃分析设定。
  • 生物类似药先验依据审批早期步骤(分析相似性、动物研究、药代/药效等效性)的证据强度设定。
  • 高度分析与药代/药效相似性可为III期试验放宽统计阈值提供依据。

临床怎么用

  • 在生物类似药III期试验设计中,可考虑引入基于历史证据的先验信息进行贝叶斯分析,以潜在降低样本量并提高效率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A biologic is a product made from living organisms. A biosimilar is a new version of an already approved branded biologic. Regulatory guidelines recommend a totality-of-the-evidence approach with stepwise development for a new biosimilar. Initial steps for biosimilar development are (a) analytical comparisons to establish similarity in structure and function followed by (b) potential animal studies and a human pharmacokinetics/pharmacodynamics equivalence study. The last step is a phase III clinical trial to confirm similar efficacy, safety, and immunogenicity between the biosimilar and the biologic. A high degree of analytical and pharmacokinetics/pharmacodynamics similarity could provide justification for an eased statistical threshold in the phase III trial, which could then further facilitate an overall abbreviated approval process for biosimilars. Bayesian methods can help in the analysis of clinical trials, by adding proper prior information into the analysis, thereby potentially decreasing required sample size. We develop proper prior information for the analysis of a phase III trial for showing that a proposed biosimilar is similar to a reference biologic. For the reference product, we use a meta-analysis of published results to set a prior for the probability of efficacy, and we propose priors for the proposed biosimilar informed by the strength of the evidence generated in the earlier steps of the approval process. A simulation study shows that with few exceptions, the Bayesian relative risk analysis provides greater power, shorter 90% credible intervals with more than 90% frequentist coverage, and better root mean squared error.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Weiss RE, Xia X, Zhang N, et al. Bayesian methods for analysis of biosimilar phase III trials. Stat Med. 2018. PMID: 29797335. doi:10.1002/sim.7814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。